Publications by authors named "Y Beguin"
Background: Mesenchymal stromal cells (MSC) have immunomodulatory and hematopoiesis-supporting properties that could potentially benefit hematopoietic stem cell (HSC) engraftment and decrease the incidence and/or severity of graft-versus-host disease (GVHD).
Methods: Based on our previous pilot study, we established a multicenter, prospective, randomized, double-blind trial evaluating the efficacy of co-infusing third-party MSC (1.5-3 × 10/kg) versus placebo on the day of HSC transplantation (HCT) to prevent GVHD in recipients of HLA-mismatched unrelated donors after reduced-intensity conditioning.
Despite the growing evidence supporting the existence of CNS involvement in acute and chronic graft-versus-host disease (CNS-GvHD), the characteristics and course of the disease are still largely unknown. In this multicenter retrospective study, we analyzed the clinical, biological, radiological, and histopathological characteristics, as well as the clinical course of 66 patients diagnosed with possible CNS-GvHD (pCNS-GvHD), selected by predetermined diagnostic criteria. Results were then contrasted depending on whether pCNS-GvHD occurred before or after day 100 following allogeneic hematopoietic stem cell transplantation.
View Article and Find Full Text PDFMesenchymal stromal cells (MSCs) have immunomodulatory properties and are therefore considered promising tools in kidney transplantation. Although most studies have been conducted with autologous MSCs, using allogeneic MSCs as an off-the-shelf product is more feasible in clinical settings. However, allogeneic MSCs could potentially induce an immune response, which might eventually be directed towards the kidney allograft because of shared human leukocyte antigen (HLA) epitope mismatches between the kidney and MSC donor.
View Article and Find Full Text PDFArticle Synopsis
- Umbilical cord blood (UCB) is a valuable stem cell source for patients without a matching donor, but its transplantation can lead to longer recovery times and higher complications.
- This study aimed to assess the safety and feasibility of combining UCB transplantation with third-party mesenchymal stromal cells (MSC), focusing on treatment-related mortality (TRM) at day 100 and other outcomes.
- Results showed that the combination is feasible, with a TRM of 18% at day 100, faster recovery times for blood cell counts, and minimal cases of graft versus host disease (GVHD), suggesting it may address some challenges associated with UCB transplantation.
Article Synopsis
- Nocardiosis is a serious infection that can occur after hematopoietic cell transplantation (HCT), and this study aimed to identify its risk factors and the impact of certain preventive treatments.
- A review of 64 cases of nocardiosis and 128 matched controls showed that factors like tacrolimus use, low lymphocyte counts, male sex, recent corticosteroid use, and previous CMV infections increased the risk of developing this infection.
- Conversely, patients on trimethoprim-sulfamethoxazole prophylaxis had a significantly lower risk of nocardiosis; however, those who did develop it had poorer survival rates compared to controls.